Table 2 Characteristics of birthing parents and infant, by treatment allocation
| Â | Azithromycin, n (%) | Placebo, n (%) |
|---|---|---|
All birthing parents | N = 1055* | N = 1055* |
Age in years, median (IQR) | 27.4 (23.1–31.9) | 27.4 (23.2–32.3) |
Ethnicity | ||
 Other | 183 (17.3%) | 184 (17.4%) |
 iTaukei/Indigenous Fijian | 872 (82.7%) | 871 (82.6%) |
Residential location | ||
 Rural | 67 (6.4%) | 67 (6.4%) |
 Urban | 452 (42.8%) | 436 (41.3%) |
 Peri-urban | 536 (50.8%) | 552 (52.3%) |
Total number of household members, median (IQR) (N = 2110) | 6.0 (4.0–8.0) | 6.0 (4.0–8.0) |
Estimated weekly family income, $FJ median (IQR) (N = 2107) | 300.0 (200.0–400.0) | 300.0 (200.0–400.0) |
Cigarette use | 103 (9.8%) | 121 (11.5%) |
Mode of delivery (N = 2107) | ||
 Vaginal—non-instrumental | 807/1052 (76.7%) | 791 (75.0%) |
 Vaginal—instrumental | 9/1052 (0.9%) | 10 (0.9%) |
 Caesarean | 236/1052 (22.4%) | 254 (24.1%) |
Treated with other antibiotics during admission | 355/1049 (33.8%) | 396/1054 (37.6%) |
Hours between rupture of membrane and delivery, median (IQR) | 1.5 (0.2–6.3) | 1.4 (0.2–6.9) |
Hours between study drug and delivery, median (IQR) (N = 2107) | 10.2 (3.8–32.6) | 11.2 (3.9–34.3) |
 72 h or greater between administration of study drug and delivery | 125/1052 (11.9%) | 131 (12.4%) |
Multiple delivery (N = 2107)** | 6/1053 (0.6%) | 8 (0.8%) |
All newborns | N = 1059*†| N = 1063* |
Sex (N = 2121) | ||
 Female | 531/1058 (50.2%) | 504/1063 (47.4%) |
Apgar score at birth (N = 2117) | ||
 1–6 | 49/1056 (4.6%) | 35/1061 (3.3%) |
 7–10 | 1007/1056 (95.4%) | 1026/1061 (96.7%) |
Birthweight (N = 2106) | ||
 Mean (SD) | 3441.0 (493.9) | 3422.6 (496.8) |
 Low birth weight < 2500 g | 26/1050 (2.5%) | 23/1056 (2.2%) |
Gestational age (N = 2109) | ||
 Mean (SD) | 39.7 (1.4) | 39.5 (1.6) |
 Preterm birth (< 37w) | 29/1051 (2.8%) | 35/1058 (3.3%) |
Exclusive breastfeeding at 3 months | 535/952 (56.2%) | 540/972 (55.6%) |
Wasting‡ at 3 months | 28/378 (7.4%) | 22/428 (5.1%) |